Cost-utility analysis of valsartan, enalapril, and candesartan in patients with heart failure in Iran

Cost-utility analysis of valsartan, enalapril, and candesartan in patients with heart failure in Iran

Abstract Background Today, heart failure is one of the leading causes of death and disability in most developed and developing countries. By 2030, more than 23.3 million people are projected to die of cardiovascular diseases each year, and the prevalence of heart failure is expected to increase by 2...

Full description

Bibliographic Details
Main Authors: Ramin Ravangard, Farideh Sadat Jalali, Marjan Hajahmadi, Abdosaleh Jafari
Format: Article
Language:English
Published: BMC 2023-09-01
Series:Health Economics Review
Subjects:
Valsartan
Enalapril
Candesartan
Markov model
Heart failure
Cost-utility analysis
Online Access:https://doi.org/10.1186/s13561-023-00457-4

Similar Items

Similar Items